IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks

Core Insights - Ironwood Pharmaceuticals (IRWD) reported an adjusted loss of 1 cent per share for Q4 2025, missing the Zacks Consensus Estimate of earnings of 2 cents, and down from adjusted earnings of 1 cent per share in the same quarter last year [1] - Total revenues for Q4 were $47.7 million, falling short of the Zacks Consensus Estimate of $53 million, representing a year-over-year decrease of approximately 47.3% [1] Financial Performance - Ironwood's shares declined by 11.4% following the weaker-than-expected results, although the stock has increased by 166.7% over the past six months compared to a 1.1% decline in the industry [2] - Linzess, Ironwood's sole marketed product, generated net sales of $163.2 million in the U.S., down 27% year-over-year due to rebate timing issues and increased pricing pressure from Medicare Part D redesign [4] - Ironwood's share of net profit from Linzess sales in the U.S. totaled $45.2 million, reflecting a 49% decline year-over-year [5] - Total costs and expenses in Q4 were $40.9 million, down 30.8% from the previous year, while adjusted EBITDA was $10.9 million, a decrease of 70.7% year-over-year [8] Full-Year Results and Guidance - For the full year 2025, Ironwood generated revenues of $296.2 million, a decrease of approximately 15.7% year-over-year, with adjusted earnings of 25 cents per share, up from 4 cents in the prior year [9] - The company reiterated its 2026 revenue guidance of $450 million to $475 million, with U.S. sales of Linzess expected to be between $1.13 billion and $1.18 billion [10] - Ironwood anticipates adjusted EBITDA of over $300 million in 2026, indicating effective cost management [10] Future Outlook - Ironwood expects significant improvement in Linzess sales in 2026, with a reduction in the list price effective January 1, 2026, aimed at maintaining patient access and potentially increasing net revenues due to fewer mandatory government rebates [11] - The company is developing apraglutide for treating short bowel syndrome and has aligned with the FDA on a confirmatory phase III study design, with clinical site initiation expected in Q2 2026 [12][13] - Ironwood acquired the rights to develop apraglutide following the acquisition of VectivBio in June 2023, with a new drug application submission targeted before the end of 2029 [14]